We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Broad-Spectrum Antibiotics Ineffective as Initial Pneumonia Treatment

By HospiMedica International staff writers
Posted on 09 Mar 2020
A new study shows that hospitalized pneumonia patients prescribed antibiotics that target methicillin-resistant Staphylococcus aureus (MRSA) fare no better than standard medical care.

Researchers at the Veterans Affairs Salt Lake City Health Care System (UT, USA) and the University of Utah (UU; Salt Lake City, USA) conducted a retrospective cohort study involving 88,605 hospitalized patients (median age 70 years, predominantly men) who received either anti-MRSA or standard therapy for community-onset pneumonia. The main outcomes were 30-day all-cause mortality, after adjustment for patient comorbidities, vital signs, and laboratory results. Secondary outcomes included kidney injury and secondary infections with Clostridioides difficile, vancomycin-resistant Enterococcus species, or gram-negative bacilli.

The results revealed no discernable benefit of anti-MRSA treatment in addition to standard treatment. In fact, anti-MRSA treatment was associated with a 40 % higher risk of dying within 30 days of discharge, perhaps due to potentially severe side effects of vancomycin, including increased incidence of kidney failure and secondary infections. The researchers also observed that as doctors became more aware of MRSA infection in the lungs, they tended to use anti-MRSA drugs as initial treatment, despite the fact that MRSA only accounts for about 2% of pneumonia cases. The study was published on February 17, 2020, in JAMA Internal Medicine.

“In the absence of better tests to identify MRSA as a potential pathogen causing the disease, using anti-MRSA therapies does not seem to offer any advantage over standard treatment therapy,” said lead author Barbara Ellen Jones, MD, MSc, of UU. “Under these circumstances, it may be safer for patients if physicians to stick to standard antibiotic treatments for a couple of days to see how patients are doing, rather than leaping into anti-MRSA therapy right off the bat.”

Pneumonia is the eighth leading cause of death in the United States, accounting for more than one million hospitalizations and about 50,000 deaths each year. It can be caused by viruses, fungi, and bacteria, including MRSA.

Related Links:
Veterans Affairs Salt Lake City Health Care System
University of Utah



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Mammo 3D Performance Kits
Mammo 3D Performance Kits
New
Ultrasound Table
General 3-Section Top EA Ultrasound Table

Latest Critical Care News

Gel-Based Stretchable Triboelectric Nanogenerators to Revolutionize Wearable Technology

First Of Its Kind Wearable Sticker Accurately Monitors and Detects Changes in Breathing

Prosthetic Material Could Reduce Infections from Intravenous Catheters